Neurocrine Biosciences, Inc. $NBIX Shares Acquired by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 44.7% in the 4th quarter, HoldingsChannel reports. The fund owned 97,450 shares of the company’s stock after buying an additional 30,081 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Neurocrine Biosciences were worth $13,821,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the business. JPMorgan Chase & Co. boosted its position in shares of Neurocrine Biosciences by 11.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 4,730,152 shares of the company’s stock worth $664,019,000 after acquiring an additional 468,405 shares in the last quarter. AQR Capital Management LLC boosted its position in shares of Neurocrine Biosciences by 83.7% in the 3rd quarter. AQR Capital Management LLC now owns 2,773,648 shares of the company’s stock valued at $388,435,000 after purchasing an additional 1,263,633 shares during the period. Deerfield Management Company L.P. boosted its position in shares of Neurocrine Biosciences by 1.4% in the 3rd quarter. Deerfield Management Company L.P. now owns 1,184,345 shares of the company’s stock valued at $166,258,000 after purchasing an additional 16,543 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Neurocrine Biosciences by 3.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 710,122 shares of the company’s stock valued at $99,686,000 after purchasing an additional 25,683 shares during the period. Finally, Armistice Capital LLC boosted its position in shares of Neurocrine Biosciences by 3.1% in the 3rd quarter. Armistice Capital LLC now owns 697,022 shares of the company’s stock valued at $97,848,000 after purchasing an additional 20,998 shares during the period. 92.59% of the stock is owned by institutional investors and hedge funds.

Neurocrine Biosciences Trading Up 0.7%

Neurocrine Biosciences stock opened at $131.18 on Thursday. Neurocrine Biosciences, Inc. has a twelve month low of $101.15 and a twelve month high of $160.18. The stock has a 50 day moving average of $129.86 and a two-hundred day moving average of $138.09. The stock has a market capitalization of $13.19 billion, a price-to-earnings ratio of 28.15, a PEG ratio of 0.68 and a beta of 0.35.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Wednesday, February 11th. The company reported $1.88 EPS for the quarter, missing the consensus estimate of $2.36 by ($0.48). Neurocrine Biosciences had a return on equity of 16.48% and a net margin of 16.73%.The company had revenue of $805.50 million for the quarter, compared to analysts’ expectations of $804.21 million. During the same quarter last year, the company earned $1.69 EPS. Neurocrine Biosciences’s revenue for the quarter was up 28.3% compared to the same quarter last year. Equities analysts predict that Neurocrine Biosciences, Inc. will post 6.33 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Leerink Partners upped their target price on Neurocrine Biosciences from $160.00 to $170.00 and gave the company an “outperform” rating in a research report on Wednesday. Wall Street Zen cut Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, February 16th. Morgan Stanley upped their target price on Neurocrine Biosciences from $173.00 to $185.00 and gave the company an “equal weight” rating in a research report on Friday, April 10th. Weiss Ratings reissued a “hold (c+)” rating on shares of Neurocrine Biosciences in a research report on Thursday, January 22nd. Finally, JPMorgan Chase & Co. upped their target price on Neurocrine Biosciences from $176.00 to $177.00 and gave the company an “overweight” rating in a research report on Thursday, March 12th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, Neurocrine Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $180.67.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research?driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.